Ovid Therapeutics Inc OVID
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $2.58
- Day Range
- $2.56–2.95
- 52-Week Range
- $1.18–3.11
- Bid/Ask
- $1.14 / $3.00
- Shares Outstanding
- 195.30M
- Market Cap
- $556.60M
- Volume/Avg
- 6 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 218.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 23
- Website
- https://www.ovidrx.com
Valuation
Metric | OVID |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.51 |
Price/Sales | 218.81 |
Price/Cash Flow | — |
Price/Earnings
OVID
Financial Strength
Metric | OVID |
|---|---|
Quick Ratio | 11.75 |
Current Ratio | 12.39 |
Interest Coverage | — |
Quick Ratio
OVID
Profitability
Metric | OVID |
|---|---|
Return on Assets (Normalized) | −33.89% |
Return on Equity (Normalized) | −39.75% |
Return on Invested Capital (Normalized) | −35.98% |
Return on Assets
OVID
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#&h<Mq | LOCK|@^DL | $139B | |||
| Moderna Inc MRNA | LOCK|n>#!cw$ | LOCK|>>m | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|L!>?vX | LOCK|%t%%k | $94B | |||
| argenx SE ADR ARGX | LOCK|$<H<$@% | LOCK|%$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|P?HbJ! | LOCK|?r | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|N%nM?M^ | LOCK|g!hJ^ | $30B | |||
| Incyte Corp INCY | LOCK|%k#Pl&T | LOCK|^$G | $24B | |||
| BioNTech SE ADR BNTX | LOCK|zS%RMV | LOCK|X!& | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$#^%vM | LOCK|z$vP | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|M@QY>f | LOCK|T<K | $15B |
United States